Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis

Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic... PharmacoEconomics (2017) 35:845–858 DOI 10.1007/s40273-017-0519-z ORIGINAL RESEARCH ARTICLE Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis 1 1 2,3 2 • • • • James Buchanan Sarah Wordsworth Ruth Clifford Pauline Robbe 4,5 2,3,4,6 4,5 • • Jenny C. Taylor Anna Schuh Samantha J. L. Knight Published online: 31 July 2017 The Author(s) 2017. This article is an open access publication Abstract Results Genomic testing strategies yielded the most life- Background Genomic tests may improve the stratification years/quality-adjusted life-years per patient, but were not of patients to receive new therapies in several disease cost effective compared with a threshold of £30,000 per life- areas. However, the use of expensive targeted therapies can year/quality-adjusted life-year gained. Cost-effectiveness impact on the cost effectiveness of these tests. This study acceptability curves indicated that there was some uncer- presents an economic evaluation of genomic testing in tainty surrounding this result. A genomic testing strategy chronic lymphocytic leukaemia in the context of the UK becomes the most cost-effective option if a higher end-of-life National Health Service. cost-effectiveness threshold of £50,000 is applied, if a Methods Cost-effectiveness and cost-utility analyses (us- societal costing perspective is considered in 25-year-old http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png PharmacoEconomics Springer Journals

Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis

Loading next page...
 
/lp/springer_journal/using-genomic-information-to-guide-ibrutinib-treatment-decisions-in-3cbLUhy97e
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by The Author(s)
Subject
Medicine & Public Health; Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Health Administration; Public Health
ISSN
1170-7690
eISSN
1179-2027
D.O.I.
10.1007/s40273-017-0519-z
Publisher site
See Article on Publisher Site

Abstract

PharmacoEconomics (2017) 35:845–858 DOI 10.1007/s40273-017-0519-z ORIGINAL RESEARCH ARTICLE Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis 1 1 2,3 2 • • • • James Buchanan Sarah Wordsworth Ruth Clifford Pauline Robbe 4,5 2,3,4,6 4,5 • • Jenny C. Taylor Anna Schuh Samantha J. L. Knight Published online: 31 July 2017 The Author(s) 2017. This article is an open access publication Abstract Results Genomic testing strategies yielded the most life- Background Genomic tests may improve the stratification years/quality-adjusted life-years per patient, but were not of patients to receive new therapies in several disease cost effective compared with a threshold of £30,000 per life- areas. However, the use of expensive targeted therapies can year/quality-adjusted life-year gained. Cost-effectiveness impact on the cost effectiveness of these tests. This study acceptability curves indicated that there was some uncer- presents an economic evaluation of genomic testing in tainty surrounding this result. A genomic testing strategy chronic lymphocytic leukaemia in the context of the UK becomes the most cost-effective option if a higher end-of-life National Health Service. cost-effectiveness threshold of £50,000 is applied, if a Methods Cost-effectiveness and cost-utility analyses (us- societal costing perspective is considered in 25-year-old

Journal

PharmacoEconomicsSpringer Journals

Published: Jul 31, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off